Cold-Adapted Live Attenuated SARS-Cov-2 Vaccine Completely Protects Human ACE2 Transgenic Mice from SARS-Cov-2 Infection.

Cold-Adapted Live Attenuated SARS-Cov-2 Vaccine Completely Protects Human ACE2 Transgenic Mice from SARS-Cov-2 Infection.
复制标题

DOI:
10.3390/vaccines8040584
复制
发表时间:
2020-10-03
期刊:
影响因子:
7.8
通讯作者:
Jang Y
Jang Y
中科院分区:
医学3区
文献类型:
--
作者:
Seo SH;Jang Y

文献摘要

参考文献

被引文献

相似文献

目前迫切需要一种安全有效的疫苗,能够提供针对严重急性呼吸道综合征冠状病毒(SARS-CoV-2)的群体免疫,以阻止该病毒在人类中的传播。许多人类病毒疫苗是活的、减毒的病毒形式,其引起体液和细胞免疫。在这里,我们描述了一种冷适应减毒活疫苗(SARS-CoV-2/human/Korea/CNUHV 03-CA 22 °C/2020),该疫苗是通过在Vero细胞中逐渐适应SARS-CoV-2从37 °C到22 °C的生长而开发的。这种疫苗可以作为鼻喷雾剂潜在地施用于人类。其单次剂量强烈诱导鼻内免疫K18-hACE 2小鼠的中和抗体(滴度> 640)、细胞免疫和粘膜伊加抗体,这些小鼠对SARS-CoV-2和SARS-CoV感染非常敏感。单剂量接种疫苗的小鼠完全免受SARS-CoV-2感染,并且没有显示体重减轻,死亡或组织中存在病毒,如鼻甲,脑,肺和肾脏。这些结果表明,我们已经开发的SARS-CoV-2冷适应减毒活疫苗可能是一个候选的SARS-CoV-2疫苗的人。
A safe and effective vaccine that can provide herd immunity against severe acute respiratory syndrome coronavirus (SARS-CoV-2) is urgently needed to stop the spread of this virus among humans. Many human viral vaccines are live, attenuated forms of viruses that elicit humoral and cellular immunity. Here, we describe a cold-adapted live-attenuated vaccine (SARS-CoV-2/human/Korea/CNUHV03-CA22 °C/2020) developed by gradually adapting the growth of SARS-CoV-2 from 37 °C to 22 °C in Vero cells. This vaccine can be potentially administered to humans as a nasal spray. Its single dose strongly induced neutralising antibodies (titre > 640), cellular immunity, and mucosal IgA antibodies in intranasally immunised K18-hACE2 mice, which are very susceptible to SARS-CoV-2 and SARS-CoV infections. The one-dose vaccinated mice were completely protected from SARS-CoV-2 infection and did not show body weight loss, death, or the presence of virus in tissues, such as the nasal turbinates, brain, lungs, and kidneys. These results demonstrate that the cold-adapted live attenuated SARS-CoV-2 vaccine we have developed may be a candidate SARS-CoV-2 vaccine for humans.
DOI: 10.1038/s41564-020-0695-z
发表时间: 2020-04-01
影响因子: 28.3
作者:
Gorbalenya, Alexander E.;Baker, Susan C.;Ziebuhr, John
通讯作者: Ziebuhr, John
DOI: 10.1016/s0140-6736(20)30183-5
发表时间: 2020-02-15
期刊: LANCET
影响因子: 168.9
作者:
Huang, Chaolin;Wang, Yeming;Cao, Bin
通讯作者: Cao, Bin
DOI: 10.1099/jgv.0.001453
发表时间: 2020-09
期刊: The Journal of general virology
影响因子: --
作者:
Ogando NS;Dalebout TJ;Zevenhoven-Dobbe JC;Limpens RWAL;van der Meer Y;Caly L;Druce J;de Vries JJC;Kikkert M;Bárcena M;Sidorov I;Snijder EJ
通讯作者: Snijder EJ
DOI: 10.1586/14760584.6.1.11
发表时间: 2007-02-01
影响因子: 6.2
作者:
O'Ryan, Miguel
通讯作者: O'Ryan, Miguel
DOI: 10.1128/jvi.02012-06
发表时间: 2007-01-01
影响因子: 5.4
作者:
McCray, Paul B., Jr.;Pewe, Lecia;Perlman, Stanley
通讯作者: Perlman, Stanley